Publications

Mass vaccination: when and why.

HEYMANN, DL; Aylward, RB;

2006

Current topics in microbiology and immunology, (2006).304, 10.1007/3-540-36583-4_1.

Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales.

Trotter, CL; EDMUNDS, WJ; Ramsay, ME; MILLER, E;

2006

Human vaccines, (2006).2 2 10.4161/hv.2.2.2611.

Perspective: determinants of the severity of poliovirus outbreaks in the post eradication era.

FINE, PE M; Ritchie, S;

2006

Risk analysis, (2006).26 6 10.1111/j.1539-6924.2006.00855.x.

Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.

Castellsagué, X; Díaz, M; De Sanjosé, S; Muñoz, N; Herrero, R; Franceschi, S; PEELING, RW; Ashley, R; Smith, JS; Snijders, PJ F; Meijer, CJ L M; Bosch, FX; International Agency for Research on Cancer Multic,;

2006

Journal of the National Cancer Institute, (2006).98 5 10.1093/jnci/djj067.

Revaccination with Bacillus Calmette-Guerin (BCG) vaccine does not reduce morbidity from malaria in African children.

Rodrigues, A; SCHELLENBERG, JA; Roth, A; Benn, CS; Aaby, P; GREENWOOD, B;

2006

Tropical medicine & international health, (2006).12 2 10.1111/j.1365-3156.2006.01766.x.

Community-based monitoring of diarrhea in urban Brazilian children: incidence and associated pathogens.

Barreto, ML; Milroy, CA; Strina, A; Prado, MS; Leite, JP; Ramos, EA G; Ribeiro, H; Alcântara-Neves, NM; Teixeira, MD G; RODRIGUES, LC; Ruf, H; Guerreiro, H; Trabulsi, LR;

2006

Transactions of the Royal Society of Tropical Medicine and Hygiene, (2006).100 3 10.1016/j.trstmh.2005.03.010.

New strategies for the elimination of polio from India.

Grassly, NC; Fraser, C; Wenger, J; Deshpande, JM; Sutter, RW; HEYMANN, DL; Aylward, RB;

2006

Science (New York, NY), (2006).314 5802 10.1126/science.1130388.

The cost-effectiveness of antenatal varicella screening with post-partum vaccination of susceptibles.

Pinot de Moira, A; EDMUNDS, WJ; Breuer, J;

2006

Vaccine, (2006).24 9 10.1016/j.vaccine.2005.09.028.

A live experimental vaccine against Burkholderia pseudomallei elicits CD4+ T cell-mediated immunity, priming T cells specific for 2 type III secretion system proteins.

Haque, A; Chu, K; Easton, A; Stevens, MP; Galyov, EE; Atkins, T; Titball, R; BANCROFT, GJ;

2006

The Journal of infectious diseases, (2006).194 9 10.1086/508217.

Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control.

Thornton, V; Lennon, D; Rasanathan, K; O'Hallahan, J; Oster, P; Stewart, J; Tilman, S; Aaberge, I; Feiring, B; Nokleby, H; Rosenqvist, E; White, K; Reid, S; MULHOLLAND, K; Wakefield, MJ; Martin, D;

2006

Vaccine, (2006).24 9 10.1016/j.vaccine.2005.09.043.